Considering the past and present findings together, we suggest that our developed S100A8/A9-mAb (Ab45) (40) combined with the LOXL4-mAb will be more effective than any single inhibitor for the prevention of breast cancer outgrowth. Here, LOXL4 is linked to breast carcinoma.